John David Finley

All filings by John David Finley on record concern Palisade Bio, Inc., in the capacity of finance chief. In total, 35 filings cover trades dated from 27 August 2021 to 6 October 2026.

Both buying and selling appear: 11 purchases worth €75k, against 1 sale worth €265k. Netting one side against the other leaves €190k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 17 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Half of the purchases are above €4,448 and half below. Of 11 purchases, 7 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 9 purchases with a full 90-day history, the hit rate stands at 22% and the median 90-day move at -23.7%. This is a record of the past, not a forecast.

On 7 October 2026 came the latest disclosure, an option exercise in Palisade Bio, Inc. The last insider purchase was made public on 28 May 2024, 873 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.